Celldex Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Celldex Therapeutics is Anthony Marucci, benoemd in May2003, heeft een ambtstermijn van 21.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.36M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.061% van de aandelen van het bedrijf, ter waarde $ 1.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.4 jaar en 11.8 jaar.
Belangrijke informatie
Anthony Marucci
Algemeen directeur
US$8.4m
Totale compensatie
| Percentage CEO-salaris | 8.6% |
| Dienstverband CEO | 21.5yrs |
| Eigendom CEO | 0.06% |
| Management gemiddelde ambtstermijn | 8.4yrs |
| Gemiddelde ambtstermijn bestuur | 11.8yrs |
Recente managementupdates
Recent updates
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns
Jun 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jun 05We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$154m |
| Jun 30 2024 | n/a | n/a | -US$150m |
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$8m | US$721k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$125m |
| Jun 30 2023 | n/a | n/a | -US$113m |
| Mar 31 2023 | n/a | n/a | -US$119m |
| Dec 31 2022 | US$5m | US$693k | -US$112m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$100m |
| Mar 31 2022 | n/a | n/a | -US$77m |
| Dec 31 2021 | US$6m | US$669k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$66m |
| Mar 31 2021 | n/a | n/a | -US$64m |
| Dec 31 2020 | US$3m | US$644k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$1m | US$619k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$50m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$50m |
| Dec 31 2018 | US$1m | US$608k | -US$151m |
| Sep 30 2018 | n/a | n/a | -US$146m |
| Jun 30 2018 | n/a | n/a | -US$165m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$2m | US$598k | -US$93m |
Compensatie versus markt: De totale vergoeding ($USD 8.36M ) Anthony } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.43M ).
Compensatie versus inkomsten: De vergoeding van Anthony is gestegen terwijl het bedrijf verliesgevend is.
CEO
Anthony Marucci (62 yo)
21.5yrs
Tenure
US$8,361,844
Compensatie
Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 21.5yrs | US$8.36m | 0.061% $ 1.1m | |
| Founder | 21.5yrs | US$3.42m | 0.011% $ 192.9k | |
| Senior VP | 7.3yrs | US$2.95m | 0.042% $ 737.4k | |
| Senior Vice President of Regulatory Affairs | 7.1yrs | US$2.94m | 0.020% $ 350.9k | |
| Senior VP & Chief Medical Officer | 5.4yrs | US$2.97m | 0.026% $ 448.8k | |
| Co-Founder & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Corporate Affairs & Administration | 7.4yrs | geen gegevens | 0.0028% $ 48.7k | |
| Senior VP & General Counsel | 3.8yrs | US$2.17m | 0.053% $ 929.8k | |
| Chief Business Officer & Senior VP | 13.3yrs | geen gegevens | geen gegevens | |
| Chief Product Development Officer & Senior VP | 10.3yrs | US$1.18m | 0.014% $ 238.0k | |
| Chief Commercial Officer & Senior VP | 9.3yrs | US$563.17k | 0.031% $ 546.2k |
8.4yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CLDX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 15.9yrs | US$8.36m | 0.061% $ 1.1m | |
| Co-Founder & Member of Scientific Advisory Board | 3.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 27.8yrs | US$371.19k | 0.0042% $ 73.2k | |
| Independent Director | 16.7yrs | US$364.94k | 0.0039% $ 67.1k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 7.7yrs | US$377.44k | 0.0033% $ 57.8k | |
| Independent Chair of the Board of Directors | 23.5yrs | US$385.77k | 0.0042% $ 73.1k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 7.4yrs | US$373.27k | 0.0010% $ 17.4k | |
| Independent Director | 2.4yrs | US$367.02k | 0% $ 0 |
11.8yrs
Gemiddelde duur
72yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CLDX zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).